EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Implementation and real-world feasibility of a digital psoriasis self-management app: a 12-month prospective observational study

Implementierung und Real-World-Umsetzbarkeit einer digitalen Psoriasis-Selbstmanagement-App: 12-monatige prospektive Beobachtungsstudie

Caroline Glatzel, Oliver Steffens, Özlem Kiesel, Patrick-Pascal Strunz, Tassilo Dege, Lara Leichtfuss, Iana Bychkova, Theresa Schulze-Hagen, Marco Stumpf, Astrid Gößwein, Robert Drews, Matthias Goebeler und 4 weitere

Frontiers in Digital Health · 03.11.2026 · 8

DOI: 10.3389/fdgth.2026.1859965 ↗

Auf einen Blick

In 182 Personen mit Psoriasis war eine digitale Selbstmanagement-App über 12 Monate im Versorgungsalltag umsetzbar. Klinische und patientenberichtete Werte nahmen ab, ein Zusammenhang mit der App-Nutzung zeigte sich nicht.

Fragestellung

Wie umsetzbar ist eine digitale Selbstmanagement-App für Psoriasis im Versorgungsalltag, und wie hängt die App-Nutzung mit klinischen und patientenberichteten Outcomes zusammen?

Methode

Explorative, einarmige Feasibility-Studie in 2 deutschen universitären dermatologischen Ambulanzen; Beobachtung über 12 Monate mit Erhebungen zu V0, V1 und V2.

Ergebnisse

182 Teilnehmende. Aktivierung 70,3 % (128/182), sustained engagement 66,5 % (121/182), Foto-Upload 61,5 % (112/182), 12-Monats-Retention 58,2 % (106/182). PASI, DLQI und HADS-A sanken; HADS-D nicht nach Korrektur signifikant.

Einschränkungen

Unkontrolliertes einarmiges Design; Attrition mit möglicher Selektion zu milderer Erkrankung; keine Dosis-Wirkungs-Beziehung.

Schlussfolgerung der Autor:innen

Die Integration der App in die Routineversorgung war machbar. Die Veränderungen der klinischen und patientenberichteten Maße sind wegen des Designs und der fehlenden Dosis-Wirkungs-Beziehung hypothesengenerierend.

Kernaussagen

  • Aktivierung der App bei 70,3 %
  • 12-Monats-Retention 58,2 %
  • Keine Assoziation zwischen Nutzungsfrequenz und Outcome-Änderungen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Digital Health, online erschienen am 03.11.2026. Verfasst von Caroline Glatzel und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis impairs physical and mental health. Evidence for real-world digital disease-management interventions remains limited.

Objective

This exploratory, single-arm feasibility study assessed real-world feasibility and usage patterns of a digital self-management app for psoriasis over 12 months and explored associations between app engagement and clinical and patient-reported outcomes in two German university dermatology outpatient settings.

Methods

182 participants with psoriasis were enrolled and given access to a study app for continuous disease monitoring and weekly patient-reported outcomes. Assessments were conducted at baseline (V0), 6 months (V1) and 12 months (V2). Primary outcomes were feasibility measures: installation, activation (≥1 app login after installation), 12-month retention and sustained engagement (≥10 logins over 12 month, corresponding to ≈20% of study weeks). Changes in the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale (HADS) were analysed as exploratory outcomes.

Results

All 182 participants installed the app, a condition of enrolment. Activation was achieved by 70.3% (128/182), sustained engagement 66.5% (121/182), photo upload 61.5% (112/182) an 12 month retention 58.2% (106/182). In paired complete-case analyses, PASI (median 3.0 → 1.0, n = 104; p < 0.001), DLQI (7.0 → 3.0, n = 91; p < 0.001), and HADS-A (7.0 → 5.0, n = 93; p = 0.002) declined significantly after Bonferroni correction ( α = 0.00625); HADS-D (5.0 → 4.0, n = 93; p = 0.033) did not survive correction. The HADS-A baseline median of 7 was already below the borderline-caseness threshold of 8, so this reduction does not represent threshold crossing. In a sensitivity analysis of 75 patients with stable therapy (54, 72.0%, with sustained engagement), within-person PASI change was −0.75 points ( n = 56; 95% CI −1.2 to −0.05; p < 0.001); the DLQI change was smaller (median 0.0, mean −2.5; n = 52; p = 0.012). Higher app use frequency was not associated with greater changes in any outcome.

Conclusion

Integrating a digital self-management app into routine psoriasis care is feasible in a real-world setting, with 70.3% activation and 58.2% twelve-month retention. Clinical and patient-reported measures declined over the study period, but given the uncontrolled, single-arm design, attrition-related selection toward milder disease, and the absence of a dose-response relationship with app use, these changes cannot be attributed to the app and should be regarded as hypothesis-generating for a future randomised controlled trial. Clinical Trial Registration https://www.drks.de/search/de/trial/DRKS00037907/details , Deutsches Register Klinischer Studien DRKS00037907.

Schlagwörter

Stichwörter der Autor:innen

digital healthdigital therapeuticsfeasibilitymobile applicationpatient-reported outcomespsoriasisreal-world evidenceself-management

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
  • Department of Internal Medicine II, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany.
  • Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, University of Heidelberg, and Center of Excellence in Dermatology Mannheim, Mannheim, Germany.
  • DataSpark GmbH, Frankfurt am Main, Germany.
  • Division of Rheumatology, Department of Medicine V, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Mannheim Institute for Innate Immunoscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Förderung

  • Novartis Pharma

Zitieren

APA

Glatzel, C., Steffens, O., Kiesel, Ö., Strunz, P. P., Dege, T., Leichtfuss, L., Bychkova, I., Schulze-Hagen, T., Stumpf, M., Gößwein, A., Drews, R., Goebeler, M., Schmalzing, M., Leipe, J., Olsavszky, V., & Schmieder, A. (2026). Implementation and real-world feasibility of a digital psoriasis self-management app: a 12-month prospective observational study. Frontiers in Digital Health, 8. https://doi.org/10.3389/fdgth.2026.1859965

Vancouver

Glatzel C, Steffens O, Kiesel Ö, Strunz PP, Dege T, Leichtfuss L, et al. Implementation and real-world feasibility of a digital psoriasis self-management app: a 12-month prospective observational study. Frontiers in Digital Health. 2026;8. doi:10.3389/fdgth.2026.1859965

BibTeX
@article{Glatzel2026,
  author = {Glatzel, Caroline and Steffens, Oliver and Kiesel, Özlem and Strunz, Patrick-Pascal and Dege, Tassilo and Leichtfuss, Lara and Bychkova, Iana and Schulze-Hagen, Theresa and Stumpf, Marco and Gößwein, Astrid and Drews, Robert and Goebeler, Matthias and Schmalzing, Marc and Leipe, Jan and Olsavszky, Victor and Schmieder, Astrid},
  title = {Implementation and real-world feasibility of a digital psoriasis self-management app: a 12-month prospective observational study},
  journal = {Frontiers in Digital Health},
  year = {2026},
  volume = {8},
  doi = {10.3389/fdgth.2026.1859965}
}
Kostenlos starten →